SEARCH HEALTH CONDITIONS BY ALPHABETS
Melanoma, Metastatic
Medications for Melanoma, Metastatic
About Melanoma, Metastatic: Metastatic melanoma is where the skin cells has spread to areas of the body remote from the site of the main tumor.
Drugs Used in the Treatment of Melanoma, Metastatic
This set of medications have been utilized in the treatment of this illness, or somehow associated with.
| Medication name | Rx / OTC | Pregnancy | CSA | Alcohol | Reviews | Rating | Popularity |
|---|---|---|---|---|---|---|---|
| Mekinist | Rx | D | N | 1 inspection | 9.0 | ||
Generic title: trametinib systemic Medication course: multikinase inhibitors For consumers: dosage, interactions, side effects For specialists: AHFS DI Monograph, Prescribing Information | |||||||
| Yervoy | Rx | C | N | Insert inspection | 0.0 | ||
Generic title: ipilimumab systemic Medication course: anti-CTLA-4 monoclonal antibodies For consumers: dosage, interactions, side effects For specialists: AHFS DI Monograph, Prescribing Information | |||||||
| Tafinlar | Rx | D | N | Two reviews | 7.5 | ||
Generic title: dabrafenib systemic Medication course: multikinase inhibitors For consumers: dosage, interactions, side effects For specialists: AHFS DI Monograph, Prescribing Information | |||||||
| Zelboraf | Rx | D | N | 4 reviews | 6.6 | ||
Generic title: vemurafenib systemic Medication course: multikinase inhibitors For consumers: dosage, interactions, side effects For specialists: AHFS DI Monograph, Prescribing Information | |||||||
| Keytruda | Rx | D | N | 5 reviews | 8.0 | ||
Generic title: pembrolizumab systemic Medication course: anti-PD-1 monoclonal antibodies For consumers: dosage, interactions, side effects For specialists: AHFS DI Monograph, Prescribing Information | |||||||
| ipilimumab | Rx | C | N | Insert inspection | 0.0 | ||
Generic title: ipilimumab systemic Brand title: Yervoy Medication course: anti-CTLA-4 monoclonal antibodies For consumers: dosage, interactions, For specialists: A-Z Drug Facts, AHFS DI Monograph | |||||||
| nivolumab | Rx | N | 4 reviews | 8.0 | |||
Generic title: nivolumab systemic Brand title: Opdivo Medication course: anti-PD-1 monoclonal antibodies For consumers: dosage, interactions, For specialists: A-Z Drug Facts, AHFS DI Monograph | |||||||
| Opdivo | Rx | N | 3 reviews | 0.0 | |||
Generic title: nivolumab systemic Medication course: anti-PD-1 monoclonal antibodies For consumers: dosage, interactions, side effects For specialists: AHFS DI Monograph, Prescribing Information | |||||||
| Cotellic | Rx | N | Insert inspection | 0.0 | |||
Generic title: cobimetinib systemic Medication course: multikinase inhibitors For consumers: dosage, interactions, side effects For specialists: AHFS DI Monograph, Prescribing Information | |||||||
| trametinib | Rx | D | N | 1 inspection | 9.0 | ||
Generic title: trametinib systemic Brand title: Mekinist Medication course: multikinase inhibitors For consumers: dosage, interactions, For specialists: A-Z Drug Facts, AHFS DI Monograph | |||||||
| vemurafenib | Rx | D | N | 4 reviews | 6.6 | ||
Generic title: vemurafenib systemic Brand title: Zelboraf Medication course: multikinase inhibitors For consumers: dosage, interactions, For specialists: A-Z Drug Facts, AHFS DI Monograph | |||||||
| dabrafenib | Rx | D | N | Two reviews | 7.5 | ||
Generic title: dabrafenib systemic Brand title: Tafinlar Medication course: multikinase inhibitors For consumers: dosage, interactions, For specialists: A-Z Drug Facts, AHFS DI Monograph | |||||||
| pembrolizumab | Rx | D | N | 5 reviews | 8.0 | ||
Generic title: pembrolizumab systemic Brand title: Keytruda Medication course: anti-PD-1 monoclonal antibodies For consumers: dosage, interactions, For specialists: A-Z Drug Facts, AHFS DI Monograph | |||||||
| temozolomideAway Tag | Rx | D | N | Two reviews | 5.0 | ||
Generic title: temozolomide systemic Medication course: alkylating agents For consumers: dosage, interactions, For specialists: A-Z Drug Facts, AHFS DI Monograph, Prescribing Information Off-label: Yes | |||||||
| isotretinoinAway Tag | Rx | X | N | X | Insert inspection | 0.0 | |
Generic title: isotretinoin systemic Medication course: miscellaneous antineoplastics, mixed uncategorized representatives For consumers: dosage, interactions, For specialists: A-Z Drug Facts, AHFS DI Monograph, Prescribing Information Off-label: Yes | |||||||
| Braftovi | Rx | N | Insert inspection | 0.0 | |||
Generic title: encorafenib systemic Medication course: multikinase inhibitors For consumers: dosage, interactions, side effects For specialists: AHFS DI Monograph, Prescribing Information | |||||||
| Imlygic | Rx | N | Insert inspection | 0.0 | |||
Generic title: talimogene laherparepvec systemic Medication course: miscellaneous antineoplastics For consumers: dosage, interactions, side effects For specialists: AHFS DI Monograph, Prescribing Information | |||||||
| Mektovi | Rx | N | Insert inspection | 0.0 | |||
Generic title: binimetinib systemic Medication course: multikinase inhibitors For consumers: dosage, interactions, side effects For specialists: AHFS DI Monograph, Prescribing Information | |||||||
| PegIntron | Rx | C | N | Insert inspection | 0.0 | ||
Generic title: peginterferon alfa-2b systemic Medication category: Anti-neoplastic interferons, antiviral interferons For consumers: dosage, interactions, side effects For specialists: Prescribing Information | |||||||
| Sylatron | Rx | C | N | Insert inspection | 0.0 | ||
Generic title: peginterferon alfa-2b systemic Medication category: Anti-neoplastic interferons, antiviral interferons For consumers: dosage, interactions, side effects For specialists: Prescribing Information | |||||||
| peginterferon alfa-2b | Rx | C | N | Insert inspection | 0.0 | ||
Generic title: peginterferon alfa-2b systemic Brand names: PegIntron, Sylatron Medication category: Anti-neoplastic interferons, antiviral interferons For consumers: dosage, interactions, For specialists: A-Z Drug Facts | |||||||
| dacarbazine | Rx | C | N | Insert inspection | 0.0 | ||
Generic title: dacarbazine systemic Medication course: alkylating agents For consumers: dosage, interactions, For specialists: A-Z Drug Facts, AHFS DI Monograph, Prescribing Information | |||||||
| aldesleukin | Rx | C | N | Insert inspection | 0.0 | ||
Generic title: aldesleukin systemic Brand title: Proleukin Medication course: miscellaneous antineoplastics, interleukins For consumers: dosage, interactions, For specialists: A-Z Drug Facts, AHFS DI Monograph | |||||||
| cobimetinib | Rx | N | Insert inspection | 0.0 | |||
Generic title: cobimetinib systemic Brand title: Cotellic Medication course: multikinase inhibitors For consumers: dosage, interactions, For specialists: A-Z Drug Facts, AHFS DI Monograph | |||||||
| talimogene laherparepvec | Rx | N | Insert inspection | 0.0 | |||
Generic title: talimogene laherparepvec systemic Brand title: Imlygic Medication course: miscellaneous antineoplastics For consumers: dosage, interactions, For professionals: az Drug Facts, AHFS DI Monograph | |||||||
Legend
| Rx | Prescription Only |
|---|---|
| OTC | Over the Counter |
| Rx/OTC | Prescription or Over The Counter |
| Off Label | This medication might not be approved by the FDA for the treatment of the illness. |
| Pregnancy Category | |
|---|---|
| A | Adequate and well-controlled studies have failed to present a risk to the embryo in the first trimester of pregnancy (and there isn`t any evidence of risk in later trimesters). |
| B | Animal reproduction studies have failed to show a risk to the fetus and there are no sufficient and well-controlled studies in elderly women. |
| C | Animal research studies have demonstrated a negative effect on the fetus and there are no sufficient and well-controlled studies in humans, but possible benefits may warrant used in pregnant women despite potential risks. |
| D | There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but possible benefits may justify used in pregnant women despite potential risks. |
| X | Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved with used in elderly women obviously outweigh potential rewards. |
| N | FDA has not classified the medication. |
| Controlled Substances Act (CSA) Schedule | |
|---|---|
| N | Is not at the mercy of the Controlled Substances Act. |
| 1 | includes a higher possibility of misuse. Has no currently accepted medical use in treatment in the USA. There is just a lack of accepted safety for use under medical supervision. |
| Two | includes a higher possibility of misuse. Has a currently accepted medical use in treatment in the USA or a currently accepted medical use with severe restrictions. Abuse may cause acute psychological or physical dependency. |
| 3 | Has a possibility for abuse less than people in schedules 1 and 2 two. Has a currently accepted medical use in treatment in the USA. Abuse may lead to moderate or low physical dependence or high psychological dependence. |
| 4 | includes a minimal potential for abuse in accordance with people in schedule 3. It has a currently accepted medical use in treatment in the USA. Abuse may lead to limited physical dependence or psychological dependence relative to people in schedule 3. |
| 5 | includes a minimal potential for abuse in accordance with people in schedule 4. Has a currently accepted medical use in treatment in the USA. Abuse may lead to limited physical dependence or psychological dependence. |
| Infection | |
|---|---|
| X | Interacts with Medication. |
Browse Treatment Options
- A
- B
- C
- D
- E
- F
- G
- H
- I
- J
- K
- L
- M
- N
- O
- P
- Q
- Janin
- S
- T
- U
- V
- W
- X
- Y
- Z
Further advice
Always seek advice from with your healthcare provider to be sure the information displayed on this page pertains to your circumstances.
Top USA Pharma Companies
Popular Categories
Easily find an affordable health insurance plan
